Analyst Expectations For Janux Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed evaluations for Janux Therapeutics (NASDAQ:JANX) over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target is $65.2, with a high of $100.00 and a low of $42.00. Recent analyst actions include a lowered target by Scotiabank and maintained targets by Cantor Fitzgerald and Wedbush.
August 09, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed evaluations for Janux Therapeutics, with a 12-month price target averaging $65.2. Recent actions include Scotiabank lowering its target to $42.00 and Cantor Fitzgerald maintaining its target at $100.00.
The mixed analyst ratings and varied price targets suggest uncertainty about Janux Therapeutics' short-term performance. The lowered target by Scotiabank could exert downward pressure, while the maintained high target by Cantor Fitzgerald could provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100